A lesson in why you need to pay *very* close attention to word choice in company PR vs a true catalyst
Sad to see companies you believed in let you down right? 😞 $Shuttle Pharmaceuticals (SHPH.US)$ saying "Announces Issuance of U.S. Patent" sounds an awful lot like "awarded a patent to sell a drug based on FDA indication for treatment".
Huge difference though! Getting a patent application through doesn't mean anything revenue wise. You are only getting IP rights on the "idea" of the technology. It has nothing to do with any drugs that actually use the technology (yet).
It's not by accident a press release is phrased that way; the company knows what it's doing. Honestly, using the absurdly broad phase "Treatment of Human Disease" points more towards them trying to patent troll than anything IMO.
The technology is only intended to treat cancer currently. There are multiple companies that already have cancer drugs with this technology on the market. The company obviously knows this. The only reason to aim the patent at such a broad scope is to claim royalty payments for any drug (cancer or otherwise) that may come out in the future.
Huge difference though! Getting a patent application through doesn't mean anything revenue wise. You are only getting IP rights on the "idea" of the technology. It has nothing to do with any drugs that actually use the technology (yet).
It's not by accident a press release is phrased that way; the company knows what it's doing. Honestly, using the absurdly broad phase "Treatment of Human Disease" points more towards them trying to patent troll than anything IMO.
The technology is only intended to treat cancer currently. There are multiple companies that already have cancer drugs with this technology on the market. The company obviously knows this. The only reason to aim the patent at such a broad scope is to claim royalty payments for any drug (cancer or otherwise) that may come out in the future.
The medical jargon roughly means drugs that affect how your DNA is packed together inside the nucleus.
Think of it like loading up a moving truck. Depending on the way you organize all the furniture/boxes, where you put the fragile items, how much space you leave for things to slide in transit, etc, it will change how likely it is anything with break as you drive the truck. If items do break, sometimes they can be fixed (e.g. super glue) or sometimes they are ruined.
A broken item is a mutation and a mutation that DNA can't fix will either cause the cell to die or become cancer. The drugs would be meant to go into the truck and fix any risky packing it sees.
This isn't the bleeding edge of cancer research either - the concept has been around a while. Moomoo won't let me hyperlink but you can find a 2011 paper on Pubmed called "Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs" if you are curious.
Oncology, in general, is a super tricky biotech field to play in. It's much harder to predict the market impact or timelines of drug candidates since all drugs will be imperfect with our current tech/science. I generally avoid it personally, even when companies aren't trying to play the confidence game 😬
Oncology, in general, is a super tricky biotech field to play in. It's much harder to predict the market impact or timelines of drug candidates since all drugs will be imperfect with our current tech/science. I generally avoid it personally, even when companies aren't trying to play the confidence game 😬
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Investing primarily in bio-tech and drug development; both big pharma for growth and start-ups for speculation
72Followers
27Following
189Visitors
Follow